6 курс / Кардиология / Дислипидемии,_атеросклероз_и_их_связь_с_ишемической_болезнью_сердца
.pdf. 1996. 1. . 14–18.
9.. ., . . :
// . 2011. . 9, 5. . 28–32.
10.. . // . 1999. 4.
. 4–11.
11.. . //
. . ., 2006. . 13–33.
12.., . . //
. 1972. 6. . 88–94.
13.. ., . ., . .
. ., 1977. 190 .
14.. ., . ., . .
// . 2007. 2. . 84–92.
15.. . // .
. ., 2006. . 7–12.
16.., . .
// . ., 1986. . 21–29.
17.. ., .
. ., 1999. 500 .
18.. .
// .
. ., 2006. . 163–169.
19.. . . ., 2006. 157 .
20.. ., . ., . .
// . . ., 2006.
. 137–162.
21.. . : //
. 1990. 8. . 5–6.
22.. ., . ., . . .
// . . 1987. 2. . 5–6.
23.. – //
. 1980. 7. . 35–44.
24.. . :
// Consilium medicum. 2007. 8. . 72–79.
25.. .
// . 2008. . 6. 11. . 14–20.
26.. . :
// . 2011. . 9. 12.
. 16–23.
27.. . .
., 2004. 191 .
28..
//
. 2009. . 8. 5. . 46–49.
: PRESSI ( HERSON )
29.. .
//
. 2011. 5. . 50–52.
30.. ., . .
// . 2012 ( ).
31.., ., ., .
,
//. 1991. 2. . 24–27.
32.. ., . .
. , 1985. 319 .
33.. . // . . 1989. 1. . 3–6.
34.. ., . . –
// . 2008. . 8, 2.
. 3–13.
35.., . . :
, // . 2008. . 44, 10. . 1309–1316.
36.. . // .
. ., 2006. . 54–67.
2.37. . . . ., 2006. 238 .
38.., . ., . . . -
-2 – //
. 2011. 1. . 39–45.
39.., ., . .
. . ., 1973. 130 .
40.., ., . ., . .
-
// . 2004. . 38.
. 29–34.
41.. .
// . , . 2004. 4. . 84–90.
42.., . ., . .
QT // . 2005. . 42. . 35–43.
43.. ., . ., . ., . .
: // . 1998. 5.
. 4–8.
44.., ., . . .
:
// Consilium Medicum. 2003. T. 5, 2. . 3–6 ( ).
45.. ., . ., . .
. ., 2004. 141 .
46.., . ., . .
// . 1998.
3. . 26–28.
47.., ., .
//
. 1990. 11. . 106–108.
48.. ., 1989. 174 .
49.Bansal S., Buring J., Rifai N. et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women // JAMA. 2007. Vol. 298. P. 309–316.
50.Baumbach G., Heistad D. Cerebral circulation in chronic arterial hypertension // Brit. Rev. Hypertension. 1988. Vol. 12. P. 89–95.
51.Berge K. et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters // Science. 2000. Vol. 290. P. 1771–1775.
52.Betteridge D., Morell J. Clinicians’ guide to lipids and coronary heart disease // London. 2003. 368 p.
53.Blackburn H. Coronary disease prevention // Adv. in Cardiol. 1977. Vol. 20, part 2.
P.10–26.
54.Bodzioch ., Orso E., Klucken J. et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease // Nat.Genet. 2004. Vol. 22. P. 347–351.
55.Cannon C., Braunwald E., McCabe C. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndrome //N. Engl. J. Med. 2004. Vol. 350. P. 1495– 1504.
56.Carolei A., Totaro R., Baldassarre M. Physiopathology of cerebral circulation // Clinica Terapeutica.1996. Vol. 147 (7–8). P. 683–685.
57.Chapman ., Ray K. et al. ( ) -
// . 2011. 1. . 4–15.
58.Christensen J., Christensen ., Dyerberg J., Shmidt E. Heart rate variability and fatty acide content of blood cell membranes: a dose respons study with n-3 fatty acids // Am. J. Clin. Nutr. 1999. Vol. 70. P. 331–337.
59.Colley K., Wolfert R., Cobble . A-
//
. 2011. 3. . 30–40.
60.Corsini A. Fluvastatini effect beyond cholesterol lowering // J. Cardiovasc. Pharmacol. Therap. 2000. Vol. 5. P. 161–175.
61.de Lemos J., Blazing ., Wividt S. et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes // JAMA.2004. Vol. 292.
P.1307–1316.
62.Doll R., Peto R. Mortality in relation to smoking: tventy years observation of male British doctors // BMJ. 1976. Vol. 2. P. 1525–1536.
63.Duez H., Fruchart J., Staels B. PPARs in inflammation atherosclerosis and thrombosis //J. Cardiovasc. Risk. 2001. Vol. 8. P. 187–194.
64.Endo A., KurodaM., Tanzawa K. Competitive inhibition of 3-hydroxy-3-methyl- glutaryl coenzyme A reductase by ML-236 A and 236 fungal metabolites, having hypocholester-olemic activity//Fed. Europ. Biochem. Soc. 1976. Vol. 72. P. 323–326.
65.ESC/EAS Guidelines for the management of dyslipidaemias // Atherosclerosis. 2011. Vol. 21751. P. S1-S44.
66.Filosa J., Blanco V. Neurovascular coupling in the mammalian brain // Exp. Physiol.
: PRESSI ( HERSON )
2007. Vol. 92. P. 641–646.
67.Fredrickson D., Lees R. A system for phenotyping hyperlipoproteinaemia // Circulation. 1965. Vol. 31. P. 321–327.
68.Goldstein J., Brown M. Binding and degradation of LDL by cultured human fibroblast // J. Biol. Chem. 1974. Vol. 249. P. 5155–5162.
69.Goldstein J., Brown M. Lipoprotein receptors cholesterol metabolism and atherosclerosis//Arch. Pathol. 1975. Vol. 99. P. 181–184.
70.Goldstein J., Brown M. Atherosclerosis: the LDL-receptor hypothesis // Metabolism. 1977. Vol. 26. P. 1257–1275.
71.Gofman J., LindgrenF., Elliott H. Ultracentrifugal studies of lipoproteins of human serum // J. Biol. Chem.1949. Vol. 179. P. 973–979.
72.Hashinski V., Ladecola C., Peterson R. et al. NINDS and Canadian Stroke Network vascular cognitive impairment harmonization standards // Stroke. 2006. Vol. 37. P. 2220– 2241.
73.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals // Lancet. 2002. Vol.
360.P. 7–22.
74.Hegele R., Vezina C., Moorgjani S. et al. A hepatic lipase gene mutation associated with heritable lipolytic deficiency // J. Clin. Endocrin. Metab. 1991. Vol. 72. P. 730–732.
75.Horton J., Goldstein J., Brown M. SREBP’s: activators of the complete program of cholesterol and fatty acid synthesis in liver// J. Clin. Investig. 2002. Vol. 109 (9). P. 1125– 1131.
76.ILLUMINATE. Cholesterol: the good, the bad, and the stopped trials // Lancet. 2006. Vol. 368. P. 2034–2037.
77.Kolodgie F., Burke A., Skorija K. at al. Lipoproten-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis // Arterioscler. Thromb. Vase. Biol. 2006. Vol. 26. P. 2523–2529.
78.Krauss R. Dense LDL and CAD // Am. J. Cardiol. 1995. Vol. 75 (suppl.B). P. 53–75.
79.Libby P., Hansson G. Involvement of the immune system in human atherogenesis: current knowledge and answered questions // Lab. Invest. 1991. Vol. 64. P. 5–15.
80.Meldahl R., Marshall R., Sheinmann M. Identification of persons at risk for sudden cardiac death // Med. Clin.N. Amer. 1988. Vol. 72. P. 1015–1031.
81.Miller ., Cannon ., MurphyS. et al. PROVE IT TIMI // Amer. Coll. Cardiol. 2008. Vol. 51. P. 724–730.
82.Moore R., Pearson T. Moderate alcohol consumption and coronary artery disease // Medicine (Baltimor). 1986. Vol. 65. P. 242–267.
83.Najarian R., Sullivan L., Kannel W. et al. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke // Arch. Intern. Med. 2006. Vol. 166. P. 106–
84.Nissen S., Yock P. Intravascular ultrasound: novel pathophysiological insights and current clinical applications // Circulation. 2001. Vol. 103. P. 604–616.
85.Nordestgaard B., Benn ., Schnohr P. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease and death in men and women // JAMA. 2007. Vol. 298. P. 299–308.
86.Nordestgaard B., Chapman J., RayK. et al. Lipoprotein (a) as a cardiovascular risk factor It Eur. Heart J. 2010. Vol. 31. P. 2844–2853.
87.Oh H., Park ., Kim H. et al. Apo E genotype as an indicator for the CHD and Alzeheimer diseases in Korean senior subjects // Atherosclerosis. 2008. Vol. 9 (suppl.). P. 114 (P024-395).
88.Osgood D. et al. Genetic variation at the scavenger receptor class type 1 gene locus determines plasma lipoprotein concentrations // Clin. Endocrin. Metab. 2003. Vol. 88.
P. 2869–2879.
89.Palinski W., Rosenfeld ., Yla-Herttuala S. et al. Low density lipoprotein undergoes oxidative modification in vivo // Proc. Natl. Acad. Sci USA. 1989. Vol. 86. P. 1372–1376.
90.Pajukanta P., Lilja H., Sinsheimer J. et al. Familial combined hyperlipidaemia is associated with upstream transcription factor 1 (USF-1) //Nat. Genet. 2004. Vol. 36. P. 371–376.
91.PROGRESS Collaborative Group. Randomised trial of a perindopril based blood- pressure-lowering regimen among 6105 patients with prior stroke or transient ischemic attack // Lancet. 2001. Vol. 358. P. 1033–1041.
92.Ross R. Atherosclerosis: an inflammatory disease //N. Engl. J. Med. 1999. Vol. 340. P. 115–126.
93.Scandinavian Simvastatin Survival Study (4S) // Am. J. Cardiol. 1993. Vol. 71.
P.393–400.
94.Solanas-Barca ., de Castro-Orios I., Bea A. et al. Apo E gene mutation in subjects with mixed HLP and a clinical diagnosis of familial combined hyperlipidaemia // The 79
3.EAS Congress 26–29 June (Gothenburg). 2011 #110.
95.Stamler J., Stamler R., Neaton J. Blood pressure, Systolic and diastolic, and cardiovascular risk: US population dataq //Arch.of Intern. Med. 1993. Vol. 153. P. 598– 615.
96.Steinberg D., Parthasarathy S., Carew T. et al. Beyond cholesterol: modifications of LDL that increase its atherogenicity //N. Engl. J. Med. 1989. Vol. 320. P. 915–924.
97.Talairach J., Tournoux P. Co-planar stereotactic atlas of the Human Brain. 1988. N- Y.-122 p.
98.Vliestra R., Kronmal R., Oberman A.et al. Effect of cigarette smoking on survival of patients with angiographically documented coronary artery disease // JAMA. 1986. Vol. 255. P. 1023–1027.
99.Wiedermann C., Kiechl S., Dunzendorfer S. et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease // J. Am. Coll. Cardiol. 1999. Vol. 34 (suppl.1). P. 1975–1981
: PRESSI ( HERSON )